share_log

上海莱士(002252.SZ):控股股东拟增持2.5亿元-5亿元公司股份

Shanghai RAAS Blood Products (002252.SZ): The controlling Shareholder plans to increase its Shareholding by 0.25 billion yuan to -0.5 billion yuan in the company's shares.

Gelonghui Finance ·  Jan 8 19:23

On January 8, Gelonghui reported that Shanghai RAAS Blood Products (002252.SZ) announced that it received a notice from its controlling Shareholder, Haiyingkang (Qingdao) Medical Technology Co., Ltd. (referred to as "Haiyingkang"), informing that Haiyingkang increased its shareholding in the company by a total of 22,933,800 shares through centralized bidding on January 7 and 8, 2025, accounting for 0.35% of the company's total share capital, with an investment amount of 155.8467 million yuan (referred to as "first Shareholding"). Haiyingkang plans to continue to increase its shareholding through centralized bidding within six months from the date of this announcement (except during periods when laws, regulations, and the business rules of the Shenzhen Stock Exchange prohibit the increase of the company's Stocks). The total planned Shareholding amount (including the amount from the first Shareholding) will not be less than 250 million yuan and not exceed 500 million yuan (all inclusive of principal and not including transaction fees). This Shareholding plan does not set a price Range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment